Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 3/20 | 0.61 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.60 |
| ▸ | GLP1R | P43220 | 2/20 | 0.60 |
| ▸ | TFPI | P10646 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397582 | 0.96 | TFPI (0.60) | VIPR1VIPR2GLP1RTFPI | |
| SCHEMBL30320494 | 0.92 | VIPR1 (0.59) | VIPR1VIPR2GLP1RTFPIOPRM1 | |
| SCHEMBL30176451 | 0.91 | VIPR1 (0.66) | VIPR1VIPR2GLP1R | |
| SCHEMBL31683259 | 0.91 | TFPI (0.64) | VIPR1VIPR2TFPIOPRM1OPRD1 | |
| SCHEMBL30467092 | 0.91 | TFPI (0.62) | VIPR1GLP1RTFPIOPRM1OPRD1 | |
| SCHEMBL30432232 | 0.91 | VIPR1 (0.65) | VIPR1VIPR2GLP1RTFPI | |
| SCHEMBL31575683 | 0.91 | VIPR1 (0.61) | VIPR1VIPR2GLP1R | |
| SCHEMBL31563800 | 0.90 | VIPR1 (0.73) | VIPR1VIPR2GLP1RTFPI | |
| SCHEMBL31182890 | 0.90 | TFPI (0.67) | VIPR1VIPR2GLP1RTFPI | |
| SCHEMBL30387150 | 0.90 | VIPR2 (0.62) | VIPR1VIPR2GLP1RTFPIOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12337030-B2 | Viral vector | VALO THERAPEUTICS OY (FI) | 2025-06-24 | — | — | US | claimed |
| US-20240390468-A1 | SURVIVIN AND MAGE-A9 DUAL-TARGETED IMMUNOTHERAPY | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2024-11-28 | — | — | US | claimed |
| US-20240390482-A1 | HIV-1 ENVELOPE GLYCOPEPTIDE NANOPARTICLES AND THEIR USES | UNIV DUKE (US) | 2024-11-28 | — | — | US | claimed |
| EP-4466278-A1 | SAPONIN-BASED ADJUVANTS AND VACCINES | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) | 2024-11-27 | — | — | EP | claimed |
| EP-4440622-A1 | SAPONIN-BASED ADJUVANTS AND VACCINES | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE (ES) | 2024-10-09 | — | — | EP | claimed |
| WO-2024186623-A1 | METHODS OF MAKING DRIED PHARMACEUTICAL COMPOSITIONS | BioVaxys Inc. (US) | 2024-09-12 | — | — | WO | claimed |
| WO-2024186646-A1 | METHODS OF MAKING LIPID ADJUVANTED COMPOSITIONS | BioVaxys Inc. (US) | 2024-09-12 | — | — | WO | claimed |
| EP-4408460-A1 | SURVIVIN AND MAGE-A9 DUAL-TARGETED IMMUNOTHERAPY | BioVaxys Inc. (US) | 2024-08-07 | — | — | EP | claimed |
| WO-2024102332-A1 | VACCINE COMPOSITIONS COMPRISING A NEOANTIGEN OF KRAS | HIMV LLC (US) | 2024-05-16 | — | — | WO | claimed |
| US-20230381309-A1 | METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA | HORIZON TECHNOLOGY FINANCE CORPORATION | 2023-11-30 | — | — | US | claimed |
| WO-2023052842-A1 | SURVIVIN AND MAGE-A9 DUAL-TARGETED IMMUNOTHERAPY | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2023-04-06 | — | — | WO | claimed |
| CN-115414494-A | Polypeptide nano vaccine and preparation method and application thereof | 南京中医药大学 | 2022-12-02 | — | — | CN | claimed |
| US-20220288184-A1 | VIRAL VECTOR | VALO THERAPEUTICS OY (FI) | 2022-09-15 | — | — | US | claimed |
| CN-109758575-B | Fully-diversified amphipathic MHC II binding polypeptide, immune carrier microsphere, preparation method and application thereof | 上海微球生物科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220143165-A1 | VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, A NEOANTIGEN AND A HYDROPHOBIC CARRIER, AND METHODS OF USE THEREOF | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-05-12 | — | — | US | claimed |
| WO-2022079490-A1 | METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| CN-114302740-A | Viral vectors | 瓦洛治疗公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3976089-A1 | VIRAL VECTOR | Valo Therapeutics Oy (FI) | 2022-04-06 | — | — | EP | claimed |
| CN-113372453-B | Fusion protein and porcine epidemic diarrhea virus S1 protein recombinant subunit vaccine | 湖南兀邦生物科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| US-11260116-B2 | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2022-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260116-B2 | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof | TP53, HLA-DRB1, CD74 | VIPR1 3601/4885VIPR2 4154/4885GLP1R 4613/4885 |
| US-20240390468-A1 | SURVIVIN AND MAGE-A9 DUAL-TARGETED IMMUNOTHERAPY | BIRC5, BIRC2, BIRC7 | VIPR1 1286/4885VIPR2 1092/4885GLP1R 2045/4885 |
| US-20230381309-A1 | METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA | PDCD1LG2, BCL6, PDCD1 | VIPR1 3683/4885VIPR2 4377/4885GLP1R 4211/4885 |
| US-20220143165-A1 | VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, A NEOANTIGEN AND A HYDROPHOBIC CARRIER, AND METHODS OF USE THEREOF | TP53, HLA-DRB1, CD74 | VIPR1 3601/4885VIPR2 4154/4885GLP1R 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.